Skip to main content

Table 1 Primary characteristics of patients and controls

From: Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients

Entity n Male (n/%) Female (n/%) Age (mean ± SD) Stage limited/advanced/unknown (n/%)
All tumors 145 89 (61.4%) 56 (38.6%) 58.8 ± 14.70 28 (19.3%)/62 (42.8%)/55 (37.9%)
 Adrenal cancers 31 13 (41.9%) 18 (58.1%) 51.3 ± 9.97 5 (16.1%)/19 (61.3%)/7 (22.6%)
 Atypical carcinoid of lung 1 0 (0.0%) 1 (100.0%) 58.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
 Breast cancer (non-neuroendocrine) 2 0 (0.0%) 2 (100.0%) 59.5 ± 1.50 0 (0.0%)/0 (0.0%)/2 (100.0%)
 Cholangiocarcinoma 4 3 (75.0%) 1 (25.0%) 70.3 ± 5.17 1 (25.0%)/2 (50.0%)/1 (25.0%)
 Colorectal cancer 1 1 (100.0%) 0 (0.0%) 60.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 CUP (non-neuroendocrine) 3 1 (33.3%) 2 (66.7%) 74.3 ± 8.06 0 (0.0%)/2 (66.7%)/1 (33.3%)
 DSRCT 9 9 (100.0%) 0 (0.0%) 29.4 ± 8.90 0 (0.0%)/0 (0.0%)/9 (100.0%)
 Ewing’s sarcoma 1 1 (100.0%) 0 (0.0%) 53.0 ± 0.00 0 (0.0%)/1 (100.0%)/0 (0.0%)
 Granulosa cell tumor 1 0 (0.0%) 1 (100.0%) 72.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 Hepatocellular carcinoma 6 3 (50.0%) 3 (50.0%) 61.3 ± 7.16 3 (50.0%)/1 (16.7%)/2 (33.3%)
 Laryngeal cancer 1 1 (100.0%) 0 (0.0%) 72.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
 Malignant paraganglioma 1 1 (100.0%) 0 (0.0%) 49.0 ± 0.00 0 (0.0%)/1 (100.0%)/0 (0.0%)
 MANEC 2 1 (50.0%) 1 (50.0%) 65.5 ± 2.50 0 (0.0%)/2 (100.0%)/0 (0.0%)
 Melanoma 2 2 (100.0%) 0 (0.0%) 66.0 ± 4.00 0 (0.0%)/0 (0.0%)/2 (100.0%)
 Mesothelioma 6 5 (83.3%) 1 (16.7%) 69.3 ± 9.59 1 (16.7%)/2 (33.3%)/3 (50.0%)
 Neuroendocrine tumors 25 17 (68.0%) 8 (32.0%) 66.3 ± 10.57 3 (12.0%)/14 (56.0%)/8 (32.0%)
 NSCLC 9 8 (88.9%) 1 (11.1%) 59.3 ± 8.56 4 (44.4%)/5 (55.6%)/0 (0.0%)
 Osteosarcoma 1 1 (100.0%) 0 (0.0%) 32.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 Ovarial cancer 1 0 (0.0%) 1 (100.0%) 73.0 ± 0.00 1 (100.0%)/0 (0.0%)/0 (0.0%)
 Pancreatic adenocarcinoma 9 6 (66.7%) 3 (33.3%) 65.3 ± 12.89 2 (22.2%)/1 (11.1%)/6 (66.7%)
 Prostate cancer 2 2 (100.0%) 0 (0.0%) 64.0 ± 8.00 0 (0.0%)/1 (50.0%)/1 (50.0%)
 Renal cell carcinoma 4 3 (75.0%) 1 (25.0%) 71.8 ± 12.75 1 (25.0%)/2 (50.0%)/1 (25.0%)
 Sarcoma 7 3 (42.9%) 4 (57.1%) 45.7 ± 18.90 2 (28.6%)/1 (14.3%)/4 (57.1%)
 Salivary gland cancer 1 1 (100.0%) 0 (0.0%) 52.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
 SCLC 13 6 (46.2%) 7 (53.8%) 62.2 ± 11.41 2 (15.4%)/7 (53.8%)/4 (30.8%)
 Thyroid cancer 1 1 (100.0%) 0 (0.0%) 61.0 ± 0.00 0 (0.0%)/1 (100.0%)/0 (0.0%)
 Undifferentiated cancer of thymus 1 0 (0.0%) 1 (100.0%) 41.0 ± 0.00 0 (0.0%)/0 (0.0%)/1 (100.0%)
Controls
 Conn’s adenom 3 3 (100.0%) 0 (0.0%) 57.7 ± 7.93 n.a
 Healthy controls 2 1 (50.0%) 1 (50.0%) 65.5 ± 2.50 n.a
  1. Table indicates the number of patients and control patients (n) separated by type of tumor entity, indicating the respective number and frequency of male and female patients (n/%), mean age of patients in years (mean ± SD) as well as the number and frequency of patients with limited, advanced and unknown tumor stage (n/%)